TSO3 AND GETINGE SIGN LETTER OF INTENT FOR GLOBAL DISTRIBUTION AGREEMENTTuesday, August 7, 2012
TSO3 AND GETINGE SIGN LETTER OF INTENT FOR GLOBAL DISTRIBUTION AGREEMENT
Quebec City, August 7, 2012 – TSO3 Inc. (“TSO3”) (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings, is pleased to announce that it has signed today a Letter of Intent with Getinge Infection Control AB (GETINGE), a division of worldwide GETINGE GROUP headquartered in Sweden, for the purpose of completing a global channel partner agreement for its new generation STERIZONE® Sterilizers.
GETINGE is the world’s largest provider of infection prevention solutions with 31 subsidiaries on six continents and over 230 distributors and partner companies in sales and service representing Getinge Infection Control.
The Letter of Intent between the two companies involves the exclusive supply and distribution of the TSO3 STERIZONE® Sterilizers to Healthcare and Life Science facilities through GETINGE’s global sales and service channel.
“We are pleased with our discussions with GETINGE”, commented Mr. Ric Rumble, TSO3’s President and CEO. “GETINGE is the hospitals’ preferred partner and supplier of equipment and service for instrument sterilization globally. We believe that our proven technology and product have global appeal and we look forward to reaching an agreement where there is a worldwide balanced approach benefiting both GETINGE and TSO3”.
“We believe that TSO3 has the ability not only to provide GETINGE with low temperature sterilization products superior to what is already in the market but also with the ability to create additional innovative offerings within our infection prevention business”, stated Anders Grahn, President and CEO of Getinge Infection Control. “We are very pleased with our assessment of the TSO3 technology and capabilities so far and look forward to a favorable outcome in our discussions with TSO3”, concluded Mr. Grahn.
About GETINGE Company and Getinge Infection Control
Getinge Infection Control (GETINGE) is one out of three business areas within Getinge AB, a publicly-listed, Swedish-based group of companies. The Getinge Infection Control business area consists of two divisions; Healthcare and Life Science. For the Healthcare sector, GETINGE provides solutions for infection control whereas for the Life Science sector, GETINGE is a key provider of solutions for contamination prevention.
Worldwide, GETINGE ranks among the leading providers of disinfectors and sterilizers within the healthcare and life sciences segments. Since its foundation in 1904, Getinge Infection Control has stood for innovation and technological progress in the field of disinfection and sterilization. Together with the other two business areas, Extended Care (ARJOHUNTLEIGH) and Medical Systems (MAQUET), the entire Getinge Group focuses on state-of-the-art medical technology.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Corporation's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
Source: TSO3 Inc.
Director – Investor and Business Relations
(418) 651-0003, Ext. 237